#ASCO22: As it dodges a takeover bid, Zymeworks wants what Daiichi Sankyo got: a massive Big Pharma partner

Kyle LaHucik

Senior Reporter

CHICAGO — The Daiichi Sankyo story made waves Sunday at the annual ASCO meeting in Chicago, as Enhertu potentially disrupted the breast cancer landscape by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO22: As it dodges a takeover bid, Zymeworks wants what Daiichi Sankyo got: a massive Big Pharma partner

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

#AS­CO22: As it dodges a takeover bid, Zymeworks wants what Dai­ichi Sankyo got: a mas­sive Big Phar­ma part­ner

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

#ASCO22: As it dodges a takeover bid, Zymeworks wants what Daiichi Sankyo got: a massive Big Pharma partner